Skip to main content

Table 2 Antiviral treatment status

From: Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China

Variable

Total (n = 8309)

Treatment duration  ≤ 24 months (n = 4275)

Treatment duration  > 24 months (n = 4034)

P value

Treatment duration (months)

24.00 (11.00–44.00)

11.00 (5.00–17.00)

46.00 (35.00–62.00)

–

ETV, n(%)

5960 (71.73)

2904 (67.93)

3056 (75.76)

 < 0.001

TDF, n(%)

1348 (16.22)

1015 (23.74)

333 (8.25)

 < 0.001

Others, n(%)

1001 (12.05)

356 (8.33)

645 (15.99)

 < 0.001

LAM exposure, n(%)

1094 (13.17)

77 (1.80)

1017 (25.21)

 < 0.001

Nucleotide analogue exposure n(%)

2556 (30.76)

1211 (28.33)

1345 (33.34)

 < 0.001

  1. ETV entecavir, TDF tenofovir disoproxil fumarate, LAM lamivudine